You have full text access to this OnlineOpen article

Dependence of surface monoclonal antibody binding on dynamic changes in FcγRIIb expression

  1. Jennifer A. Walker,
  2. Kenneth G. C. Smith

Article first published online: 24 JAN 2008

DOI: 10.1111/j.1365-2567.2007.02791.x

Issue

Immunology

Immunology

Volume 124, Issue 3, pages 412–418, July 2008

Additional Information

How to Cite

Walker, J. A. and Smith, K. G. C. (2008), Dependence of surface monoclonal antibody binding on dynamic changes in FcγRIIb expression. Immunology, 124: 412–418. doi: 10.1111/j.1365-2567.2007.02791.x

Author Information

  1. Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge, UK

*J. A. Walker, Department of Medicine, Cambridge Institute for Medical Research, Wellcome Trust/MRC building, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Email: jw425@cam.ac.uk Senior author: K. G. C. Smith, email: kcgs2@cam.ac.uk

Publication History

  1. Issue published online: 24 JAN 2008
  2. Article first published online: 24 JAN 2008
  3. Received 18 October 2007; revised 26 November 2007; accepted 28 November 2007.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (271K)

References

  • 1
    Hulett MD, Osman N, McKenzie IFC, Hogarth PM. Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG. J Immunol 1991; 147:1863–8.
  • 2
    Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9:457–92.
  • 3
    Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19–28.
  • 4
    Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005; 23:41–51.
  • 5
    Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KGC. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr Biol 2000; 10:227–30.
  • 6
    Su K, Yang H, Li X, Gibson AW, Cafardi JM, Zhou T, Edberg JC, Kimberly RP. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007; 178:3272–80.
  • 7
    Sarmay G, Rozsnyay Z, Szabo I, Biro A, Gergely J. Modulation of type II Fc gamma receptor expression on activated human B lymphocytes. Eur J Immunol 1991; 21:541–9.
    Direct Link:
  • 8
    Liu Y, Gao X, Masuda E, Redecha PB, Blank MC, Pricop L. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen–antibody complexes. J Immunol 2006; 177:8440–7.
  • 9
    Liu Y, Masuda E, Blank MC, Kirou KA, Gao X, Park MS, Pricop L. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes. J Leukoc Biol 2005; 77:767–76.
  • 10
    Rudge EU, Cutler AJ, Pritchard NR, Smith KGC. Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fc gamma RII-mediated B cell suppression. J Exp Med 2002; 195:1079–85.
  • 11
    Jiang Y, Hirose S, Sanokawa-Akakura R et al. Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 1999; 11:1685–91.
  • 12
    Stefanescu RN, Olferiev M, Liu Y, Pricop L. Inhibitory Fc gamma receptors: from gene to disease. J Clin Immunol 2004; 24:315–26.
  • 13
    McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307:590–3.
  • 14
    Jones B, Tite JP, Janeway CA Jr. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. J Immunol 1986; 136:348–56.
  • 15
    Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A 2004; 101:6104–9.
  • 16
    Han S, Collins BE, Bengtson P, Paulson JC. Homomultimeric complexes of CD22 in B cells revealed by protein–glycan cross-linking. Nat Chem Biol 2005; 1:93–7.
  • 17
    Grewal PK, Boton M, Ramirez K et al. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol 2006; 26:4970–81.
  • 18
    Razi N, Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci U S A 1998; 95:7469–74.
  • 19
    Nath D, Van Der Merwe PA, Kelm S, Bradfield P, Crocker PR. The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site. Comparison with CD22. J Biol Chem 1995; 270:26184–91.
  • 20
    Van Der Merwe PA, Crocker PR, Vinson M, Barclay AN, Schauer R, Kelm S. Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22. J Biol Chem 1996; 271:9273–80.
  • 21
    Collins BE, Blixt O, Bovin NV, Danzer CP, Chui D, Marth JD, Nitschke L, Paulson JC. Constitutively unmasked CD22 on B cells of ST6Gal I knockout mice: novel sialoside probe for murine CD22. Glycobiology 2002; 12:563–71.
  • 22
    Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of Fab and F(ab′)2 fragments from monoclonal IgG of different rat IgG subclasses. J Immunol Methods 1983; 64:141–6.
  • 23
    Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett 2002; 82:57–65.
  • 24
    Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem 2001; 276:45539–47.
  • 25
    Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood 1999; 94:233–43.
  • 26
    Pure E, Witmer MD, Lum JB, Mellman I, Unkeless JC. Properties of a second epitope of the murine Fc receptor for aggregated IgG. J Immunol 1987; 139:4152–8.
  • 27
    Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000; 96:3544–52.
  • 28
    Yamashita Y, Phee H, Tudor KS, Rossi MI, Parnes JR, Coggeshall KM, Kincade PW. A unique CD72 epitope suggests a potential interaction with Fc gamma RII/CD32 on B lineage lymphocytes. Hybridoma (Larchmt) 2006; 25:107–14.
  • 29
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443–6.
  • 30
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754–8.
  • 31
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940–7.
  • 32
    Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship. Cancer Res 2004; 64:4664–9.
  • 33
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455–9.
    Direct Link:
  • 34
    Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591–604.
  • 35
    Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005–10.
  • 36
    Kanda Y, Yamada T, Mori K et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104–18.
  • 37
    Siberil S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: the key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007; 62:26–33.
  • 38
    Winfield JB. Anti-lymphocyte antibodies in systemic lupus erythematosus. Clin Rheum Dis 1985; 11:523–49.
  • 39
    Capsoni F, Sarzi-Puttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther 2005; 7:208–14.
View Full Article (HTML) Get PDF (271K)